New Zealand markets open in 9 hours 16 minutes

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.7100-0.2100 (-7.19%)
At close: 04:00PM EDT
2.8800 +0.17 (+6.27%)
Pre-market: 08:25AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 262.68M
Enterprise value 135.90M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.78
Price/book (mrq)2.53
Enterprise value/revenue 2.10
Enterprise value/EBITDA -1.25

Trading information

Stock price history

Beta (5Y monthly) 0.46
52-week change 3-12.16%
S&P500 52-week change 325.59%
52-week high 34.2700
52-week low 31.5400
50-day moving average 32.9194
200-day moving average 32.7069

Share statistics

Avg vol (3-month) 3717.66k
Avg vol (10-day) 3768.57k
Shares outstanding 596.93M
Implied shares outstanding 696.93M
Float 854.76M
% held by insiders 133.77%
% held by institutions 147.24%
Shares short (15 Apr 2024) 44.05M
Short ratio (15 Apr 2024) 47.33
Short % of float (15 Apr 2024) 45.82%
Short % of shares outstanding (15 Apr 2024) 44.20%
Shares short (prior month 15 Mar 2024) 43.84M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -190.76%
Operating margin (ttm)-103.66%

Management effectiveness

Return on assets (ttm)-25.87%
Return on equity (ttm)-84.75%

Income statement

Revenue (ttm)64.7M
Revenue per share (ttm)0.72
Quarterly revenue growth (yoy)148.70%
Gross profit (ttm)N/A
EBITDA -123.89M
Net income avi to common (ttm)-123.43M
Diluted EPS (ttm)-1.3700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)212.2M
Total cash per share (mrq)2.2
Total debt (mrq)85.42M
Total debt/equity (mrq)82.37%
Current ratio (mrq)3.18
Book value per share (mrq)1.08

Cash flow statement

Operating cash flow (ttm)-92.17M
Levered free cash flow (ttm)-40.72M